bharat biotech

Bill Gates, former Microsoft CEO, discussed India's healthcare advancements with Union minister JP Nadda. Key areas included maternal health, immunisation, and sanitation. Gates praised India's efforts in medical cost reduction and accessible healthcare solutions globally, highlighting AI's role in future collaboration with the India AI Mission.

Biovet, part of bharat biotech, received CDSCO approval for BIOLUMPIVAXIN, a novel LSD vaccine for dairy cattle and buffaloes. Developed using the LSD virus strain from ICAR-NRCE, the vaccine distinguishes between infected and vaccinated animals, enhancing disease surveillance and supporting India's goal for a disease-free livestock population.

Biovet, part of bharat biotech, has received approval from the CDSCO for its innovative lumpy skin disease vaccine, BIOLUMPIVAXIN, for dairy cattle and buffaloes. The vaccine, developed using a strain from ICAR-NRCE, can produce 500 million doses annually and will be crucial for India's dairy sustainability and disease eradication efforts.

Telangana government has announced Rs 5445 crore investments in Green Pharma City by 11 companies, creating 9,800 jobs. Global lifesciences firms MSD, Agilisium, ALS, and Meishi Pharma also invested. CM Anumula Revanth Reddy declared a new lifesciences policy and ambitions to make the state a biosciences and biotech hub, highlighting Amgen's new facility creating 3,000 jobs.

They discussed the status of the indigenous vaccine, being developed by bharat biotech in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology, and the plans to make it available in India and the rest of the world. During the interaction, the Vice-President lauded the collaboration between the ICMR and bharat biotech and stressed the importance of public-private partnership in bringing out the indigenous "world-class product".

Vaccine major bharat biotech has joined hands with inked a licensing agreement with the Washington University School of Medicine in St. Louis for developing, conducting clinical trials, manufacturing and distributing a novel chimp-adenovirus, single dose intranasal vaccine for Covid-19.

bharat biotech is planning to launch its vaccine for Covid-19 in the second quarter next year if it gets the requisite approvals from the Indian regulatory authorities. The company's vaccine candidate- Covaxin- has been developed in collaboration with the Indian Council of Medical Research - National Institute of Virology using inactivated Sars-Cov-2, the virus that causes Covid-19.

bharat biotech, along with its Vietnamese partner Dunc Minh, is donating 2 lakh doses of indigenously developed Covid-19 vaccine Covaxin to Vietnam.

Vaccine maker bharat biotech on Tuesday said it has inked an agreement with Brazil’s Precisa Medicamentos for distribution of India’s first indigenous Covid-19 vaccine Covaxin in the Brazilian market. The Covaxin doses will be manufactured in India and exported to Brazil where they will be distributed by Precisa.

Prime Minister Narendra Modi visited vaccine maker bharat biotech’s facility at Genome Valley in Hyderabad on Saturday afternoon as part of his three-city tour to review the progress in the ongoing Covid-19 vaccine development efforts in the country.

Buoyed by the Emergency Use Authorisation approval from the Drug Controller General of India (DCGI)for its Covid-19 vaccine Covaxin, bharat biotech has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year.

Gujarat Covid Vaccine Consortium (GCVC) and bharat biotech International Limited have signed a memorandum of understanding (MoU) for the contract manufacturing of drug substance for Covaxin, the Covid-19 vaccine developed by the Hyderabad-based bharat biotech.

bharat biotech is now eyeing the Canadian market as well for its indigenously developed Covid-19 vaccine Covaxin. To this end, the company has extended its exclusive pact with US-based biopharma player Ocugen for the US market, to include Canada as well.

Union health minister Mansukh Mandaviya on Tuesday said the government has approved bharat biotech’s vaccine manufacturing facility at Ankleshwar in Gujarat for manufacturing India’s first indigenously developed Covid-19 vaccine Covaxin. The minister said the move will help ramp up availability of the indigenous vaccine for the national vaccination drive.